Cargando…

Mutation profile in Indian primary myelofibrosis patients and its clinical implications

BACKGROUND: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by abnormal proliferation of megakaryocytes, bone marrow fibrosis, and extramedullary hematopoiesis. We did mutation profile of 50 patients of PMF and tried to correlate it with initial clinical presentation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patil, Vinod R., Chandrakala, S., Mantri, Shruti, Patil, Rajesh, Wasekar, Nilesh, Jijina, Farah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	ORIGINAL ARTICLE: Hematolymphoid Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699232/ https://www.ncbi.nlm.nih.gov/pubmed/31489296 http://dx.doi.org/10.4103/sajc.sajc_276_18

Ejemplares similares

Wiskott-Aldrich Syndrome Presenting with JMML-Like Blood Picture and Normal Sized Platelets
por: Patil, Rajesh B., et al.
Publicado: (2016)

Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India
por: Suresh, Babu, et al.
Publicado: (2019)

Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib
por: Chhikara, Sunita, et al.
Publicado: (2018)

Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study
por: Dass, Jasmita, et al.
Publicado: (2019)

Langerhans cell histiocytosis: An enigmatic disease
por: Jain, Anubha, et al.
Publicado: (2019)

Impact of cytogenetics on outcomes in pediatric acute lymphoblastic leukemia
por: Chennamaneni, Rachana, et al.
Publicado: (2018)

Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India
por: Sazawal, Sudha, et al.
Publicado: (2019)

Clinico-epidemiological features and response in childhood acute lymphoblastic leukemia at regional cancer center of Northeast India
por: Saikia, Bhargab Jyoti, et al.
Publicado: (2019)

Plasmablastic lymphoma in immunocompetent and in immunocompromised patients: Experience at a regional cancer centre in India
por: Rudresha, A. H., et al.
Publicado: (2017)

Diffuse large B-cell lymphoma in elderly: Experience from a tertiary care oncology center in South India
por: Lokesh, K. N., et al.
Publicado: (2017)

Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm
por: Ghai, Shuchi, et al.
Publicado: (2017)

Translation and Pilot Validation of the EORTC QLQ-NHL-HG29 Module in Indian Languages (Hindi and Marathi) for Use in Indian Patients with Non-Hodgkin's Lymphoma
por: Patil, Roshankumar, et al.
Publicado: (2022)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
por: Ishida, Hisashi, et al.
Publicado: (2020)

Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study
por: Bankar, Aniket, et al.
Publicado: (2021)

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
por: Liang, Winnie S., et al.
Publicado: (2018)

Trend of circulating CD34(+) cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment
por: Iurlo, Alessandra, et al.
Publicado: (2022)

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
por: Pardanani, Animesh, et al.
Publicado: (2021)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
por: Ayala, Rosa, et al.
Publicado: (2023)

Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition
por: Severson, Eric A, et al.
Publicado: (2023)

Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis
por: Song, Jinming, et al.
Publicado: (2017)

The impact of SOCS1 mutations in diffuse large B‐cell lymphoma
por: Mellert, Kevin, et al.
Publicado: (2019)

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
por: Bello, Erica, et al.
Publicado: (2015)

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
por: Michel, Marc, et al.
Publicado: (2011)

Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines
por: Leupin, Nicolas, et al.
Publicado: (2006)

MicroRNA-494 Within an Oncogenic MicroRNA Megacluster Regulates G(1)/S Transition in Liver Tumorigenesis Through Suppression of Mutated in Colorectal Cancer
por: Lim, Lionel, et al.
Publicado: (2014)

Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts
por: Conte, Simona, et al.
Publicado: (2015)

An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase
por: Kohlmann, Alexander, et al.
Publicado: (2008)

A possible need for routine screening for Strongyloides stercoralis infection in Indian haemophilia patients
por: Patil, Rucha K., et al.
Publicado: (2018)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

PB2487: SECONDARY HLH: RETROSPECTIVE DATA FROM TERTIARY CARE CENTRE.
por: Wasekar, Nilesh, et al.
Publicado: (2023)

A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients
por: Zaidi, Uzma, et al.
Publicado: (2020)

2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management
por: Ali, Haris, et al.
Publicado: (2021)

Clonally unrelated Richter syndrome are truly de novo diffuse large B‐cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome
por: Favini, Chiara, et al.
Publicado: (2022)

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)
por: Gandhi, Anita K, et al.
Publicado: (2014)

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
por: Gandhi, Anita K, et al.
Publicado: (2014)

Fibrocytes in primary myelofibrosis
por: Shimoda, Kazuya, et al.
Publicado: (2021)

The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_05napdpp5meb6uleifb6vdl0eb